A clinical observation for the efficacy and safety for capetabine and Anlotinib in recurrent or metastatic head and neck malignant tumors

A phase 2 clinical study for single center for the efficacy and safety of capetabine and Anlotinib in recurrent or metastatic head and neck malignant tumors

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800019932

Enrollment

Unknown

Registered

2018-12-09

Start date

2019-01-01

Completion date

Unknown

Last updated

2018-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent or metastatic malignant tumors of the head and neck

Interventions

Case series:anlotinib

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age = 18 years old; Pathologic diagnosis was found to be a malignant tumor of the head and neck; Ability of oral-drugs and tolerance to conventional treatment; ECOG = 2 points; The survival period is more than 3 months; Pregnancy test negative for female patients without menopause; The patient voluntarily participates and signs an informed consent form;

Exclusion criteria

Exclusion criteria: Persons with serious medical diseases; People with a history of thrombosis; People with bleeding tendency or long-term anticoagulant therapy; Breastfeeding and pregnant women; Is participating in clinical trials of other new drugs

Design outcomes

Primary

Measure	Time frame
ORR;	—

Countries

China

Contacts

Public ContactZhang Xian

Second Affiliated Hospital, Dalian Medical University

17709873632@163.com+86 17709873632

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026